Guggenheim Maintains Buy on Adicet Bio, Lowers Price Target to $55
ADICET Bio, Inc. ACET
$2.97
▼ -0.67%
($-0.02)
📉 Near 52W Low
🎈 Low Float
Open
$3.00
Prev Close
$2.99
Day Range
$2.86 – $3.08
52W Range
$2.87 – $11.37
Market Cap
$27.99M
Beta
1.57
EPS (TTM)
$-13.02
📋 Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2018-01-26 |
| Shares Out. | 9,360,000 |
| Website | adicetbio.com/ ↗ |
| Phone | 13026587581 |
| Employees | 102 |
| Revenue | $0 |
| Gross Profit | $0 |
| Net Income | -$21.4M |
| Free Cash Flow | -$85.0M |
| Total Assets | $148.2M |
| Total Liabilities | $28.0M |
| Equity | $120.1M |
About ADICET Bio, Inc.
Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. It is advancing a pipeline of off-the-shelf gamma delta T cells, engineered with chimeric antigen receptors (CARs), to facilitate durable activity in patients. The company's main product candidate, prulacabtagene leucel (prula-cel), is an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, and is being developed for the potential treatment of autoimmune diseases. Additionally, it is pursuing ADI-212, a next-generation gene-edited and armored clinical candidate designed to target prostate-specific membrane antigen (PSMA).
ADICET Bio, Inc. is a publicly traded company under the ticker symbol ACET on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
12 analysts (2026-11-01)